Induction of anti-melanoma CTL response using DC transfected with mutated mRNA encoding full-length Melan-A/MART-1 antigen with an A27L amino acid substitution

Cellular Immunology

Volumn 224, Issue 2, 2003, Pages 86-97

  Abdel Wahab, Zeinab ^a   Kalady, Matthew F ^a   Emani, Sirisha ^a   Onaitis, Mark W ^a   Abdel Wahab, Omar I ^a   Cisco, Robin ^a   Wheless, Lee ^a   Cheng, Tsung Yen ^a   Tyler, Douglas S ^a   Pruitt, Scott K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

A27L mutated RNA; CTL; DC; Melan A MART 1; Melanoma

Indexed keywords

AMINO ACID; GAMMA INTERFERON; MELAN A; MESSENGER RNA; RNA;

AMINO ACID SUBSTITUTION; ANTIGEN SPECIFICITY; ARTICLE; CELL STRAIN; COMPARATIVE STUDY; CONTROLLED STUDY; DENDRITIC CELL; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; LYSIS; MELANOMA CELL; PRIORITY JOURNAL; SECRETION; T LYMPHOCYTE;

EID: 0242365635     PISSN: 00088749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellimm.2003.08.005     Document Type: Article

References (37)

1. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M., Lallas C.D., Dahm P., Niedzwiecki D., Gilboa E., Vieweg J. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumor. J. Clin. Invest. 10:2002;409-417.
2. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:1996;52-58.
3. MacKenzie M., Pshwa M.V., Wun T., Strang G., Wolf J., Gutheil J., Mason V., Caggiano F. Efficacy of idiotype-pulsed autologous dendritic cells for treatment of advanced refractory multiple myeloma. Blood. 94(Suppl. 10):1999;122a.
4. Mukherji B., Chakraborty N.G., Yamasaki S., Okino T., Yamase H., Sporn J.R., Kurtzman S.K., Ergin M.T., Ozols J., Meehan J., Mauri F. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc. Nat. Acad. Sci. USA. 92:1995;8078-8082.
5. Morse M., Deng Y., Coleman D., Hull S., Kitrell-Fisher E., Nair S.K., Schlom J., Ryback M.E., Lyerly H.K. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 5:1999;1331-1338.
6. Kundu S.K., Engelman E., Benike C., Shapero M.H., Dupuis M., Van Schooten W.C., Eibl M., Merigan T.C. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cells therapy in HIV-infected patients. AIDS Res. Hum. Retrovirus. 14:1998;551-560.
7. Small E.J., Paige F., Reese D.M., Strange G., Laus R., Peshwa M.V., Madhusudan V., Valone F.H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18:2000;3894-3903.
8. Valmori D., Scheibenbogen C., Dutoit V., Nagorsen D., Asemissen A., Rubio-Godoy V., Rimoldi D., Guillaume P., Romero P., Schadendorf D., Lipp M., Dietrich P., Thiel E., Cerottini J., Lienard D., Keilholz U. Circulating tumor-reactive CD-8+ T cells in melanoma patients contain a CD45RA+ CCR7- effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res. 62:2002;1743-1750.
9. D'Souza S., Rimoldi D., Lienard D., Lejeune F., Cerottini J.C., Romero P. Circulating Melan-A/MART-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int. J. Cancer. 78:1998;699-706.
10. Topalian S.L., Solomon D., Avis F.P., Chang A.E., Freerksen D.L., Linchan W.M., Lotz M.T., Robertson C.N., Scipp C.A., Simon P. Immunotherapy of patient with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:1988;839-853.
11. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:1991;271-296.
12. + lymphocytes as compared with nonprofessional APC J. Immunol. 167:2001;1188-1197.
13. Nestle F.O., Alijac S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
14. Romero P., Gervois N., Schneider J., Escobar P., Valmori D., Pannetier C., Steinle A., Wölfel T., Lienard D., Brichard V., Van Pel A., Jotereau F., Cerottini J.C. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201 restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 158:1997;2366-2374.
15. Valmori D., Fonteneau J.F., Lizana C., Gervois N., Lienard D., Rimoldi D., Jongeneel V., Jotereau F., Cerottini J.C., Romero P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1998;1750-1758.
16. Men Y., Miconnet I., Valmori D., Rimoldi D., Cerottini J.C., Romero P. Assessment of immunogenicity of human Melan-A peptide analogues in HLA-A*0201/Kb transgenic mice. J. Immunol. 162:1999;3566-3573.
17. Heiser A., Dahm P., Yancey D., Maurice M.A., Boczkowski D., Nair S.K., Gilboa E., Viewig J. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J. Immunol. 164:2000;5508-5514.
18. Heiser A., Maurice M.A., Yancey D.R., Wu N.Z., Dahm P., Pruitt S.K., Boczkowski D., Nair S.K., Ballo M.S., Gilboa E., Vieweg J. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 166:2001;2953-2960.
19. Heiser A., Maurice M.A., Yancey D.R., Coleman D.M., Dahm P., Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. 61:2001;3388-3393.
20. Eppler E., Horig H., Kaufman H.L., Groscurth P., Filgueria L. Carcinoembryonic antigen (CEA) presentation and specific T cell priming by human dendritic cells transfected with CEA m-RNA. Eur. J. Cancer. 38:2001;184-193.
21. Koido S., Kashiwaba M., Chen D., Gendler S., Kufe D., Gong J. Induction of antitumor immunity by vaccination with dendritic cells transfected with MUC1 RNA. J. Immunol. 165:2000;5713-5719.
22. Boczkowski D., Nair S.K., Snyder D., Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:1996;465-472.
23. Valmori D., Levy F., Miconnet L., Zajac P., Spagnoli G.C., Rimoldi D., Lienard D., Cerundolo V., Cerottini J.C., Romero P. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue. J. Immunol. 164:2000;1125-1131.
24. Morel S., Levy F., Schiltz B.-O., Brasseur F., Kepper P.-M., Peitrequin A.-L., Monsarrat B., Velthoven R., Cerottini J.-C., Boon T., Gairin J., Eynde B. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity. 12:2000;107-117.
25. Kalady M., Onaitis M., Padilla K., Emani S., Tyler D.S., Pruitt S.K. Enhanced dendritic cells antigen presentation in RNA-based immunotherapy. J. Surg. Res. 105:2000;17-24.
26. Jonuleit S., Kuhn U., Muller G., Steinbrink K., Paragnik L., Schmitt E., Knop J., Enk A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27:1997;3135-3142.
27. Abdel-Wahab Z., DeMatos P., Hester D., Dong X.D., Seigler H.F. Human dendritic cells pulsed with either melanoma tumor cell lysate or the gp100 peptide (280-288) induce pairs of T cell cultures with similar phenotype and lytic activity. Cell Immunol. 186:1998;63-74.
28. Van Tendeloo V.F., Ponsaerts P., Lardon F., Nijs G., Lenjou M., Broeckhoven C.V., Van Bockstaele D.R., Bememan Z.N. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 98:2001;49-56.
29. Banchereau J., Steinman R. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
30. Weissman D., Ni H., Scales D., Dude A., Capodici J., McGibney K., Abdool A., Isaacs S., Cannon G., Kariko K. HIV Gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response. J. Immunol. 165:2000;4710-4717.
31. Zhai Y., Yang J.C., Kawakami Y., Spiess P., Wadsworth S.C., Cardoza L.M., Couture L.A., Smith A.E., Rosenberg S.A. Antigen-specific tumor vaccine, development and characterization of recombinant adenovirus encoding MART1 or gp100 for cancer therapy. J. Immunol. 156:1996;700-710.
32. Kim C.J., Prevette T., Cormier J., Overwijk W., Roden M., Restifo N.P., Rosenberg S.A., Marincola F.M. Dendritic cells infected with poxviruses encoding MART-1/Melan-A sensitize T lymphocytes in vitro. J. Immunother. 20:1997;276-286.
33. Panelli M.C., Wunderlich J., Jeffries J., Wang E., Mixon A., Rosenberg S.A., Marincola F.M. Phase I study with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens Mart-1 and Gp100. J. Immunother. 23:2000;487-498.
34. Motta I., Andrè F., Lim A., Tartaglia J., Cox W.L., Zitvogel L., Angevin E., Kourilsky P. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J. Immunol. 167:2001;1795-1802.
35. Cella M., Scheidegger D., Lehmann P.-K., Lane P., Lanzavecchia A., Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:1996;747-752.
36. Salvatore V., Muller S., Dessing M., Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183:1996;1917-1921.
37. Fonteneau J.-F., Le Drean E., Guiner S.L., Gervois N., Diez E., Jotereau F. Heterogeneity of biological responses of melanoma-specific CTL. J. Immunol. 159:1997;2831-2839.